Skip to main content
Fig. 7 | Journal of Biomedical Science

Fig. 7

From: Dysregulation of SOX17/NRF2 axis confers chemoradiotherapy resistance and emerges as a novel therapeutic target in esophageal squamous cell carcinoma

Fig. 7

The model of SOX17/NRF2 transcription axis and ZVI@CMC treatment in ESCC. In the CCRT resistant cells, the promoter hypermethylation-induced low SOX17 protein expression causes dysregulation of the cytoprotective enzymes controlled by NRF2, and thus resulting in CCRT resistance (left). Interestingly, ZVI@CMC elicits DNMT inhibition to re-express SOX17 and suppress NRF2-mediated cytoprotective programs in ESCC, and thereby sensitizing cancer cells to CCRT treatment (right)

Back to article page

Journal of Biomedical Science

ISSN: 1423-0127